The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) is the first disease-specific instrument for pulmonary arterial hypertension (PAH) to assess patient-perceived symptoms, activity limitations and quality of life. To be able to use this questionnaire in the Netherlands, the aim of the study was to translate and validate this instrument for the Dutch-speaking population.
First the CAMPHOR was translated into Dutch (by means of a bilingual and a lay panel) and field-tested by means of cognitive debriefing interviews with ten PAH patients. For psychometric evaluation, 80 patients with PAH or chronic thromboembolic pulmonary hypertension (CTEPH) were asked to complete the CAMPHOR twice over a two-week period. To test for construct validity, participants also completed the Nottingham Health Profile (NHP).
The Dutch version of the CAMPHOR showed high internal consistency for all scales (Cronbach’s alpha 0.89–0.91) and excellent reproducibility over two weeks (reliability coefficients 0.87–0.91). Concurrent validity showed that the CAMPHOR scales correlated as expected with the NHP scales. The CAMPHOR was able to distinguish between patient groups based on self-reported general health status, disease severity and NYHA classification demonstrating evidence of known group validity. The CAMPHOR activity limitations scale correlated moderately with the distance walked during the 6‑minute walk test (r = −0.47, p < 0.01) and the symptoms scale with the Borg dyspnoea score (r = 0.51, p < 0.01).
The Dutch version of the CAMPHOR is a reliable and valid measure of quality of life and health status in patients with PAH and CTEPH is recommended for use in routine care and in clinical research.
Galie N, Humbert M, Vachiery J‑L, et al. ERS/ESC guidelines. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2015;46:903–975. CrossRef
McGoon MD, Benaz RL, Escribano-Scubias P, et al. Pulmonary Arterial Hypertension. Epidemiology and Registries. J Am Coll. 2013;62:D51–D59. CrossRef
Benza RL, Miller DP, Barst RJ, et al. An evaluation of long-term survival from the time of diagnosis in pulmonary arterial hypertension from the REVEAL registry. Chest. 2012;142:448–456. CrossRef
Kim N, Delcroix M, Jenkins DP, et al. Chronic Thomboembolic Pulmonary Hypertension. J Am Coll Cardiol. 2013;62:D92–9. CrossRef
Schölzel BE, Snijder RJ, Mager JJ, et al. Chronic thromboembolic pulmonary hypertension. Neth Heart J. 2014;22:533–541. CrossRef
Shafazand S, Goldstein MK, Doyle RL, et al. Health-Related Quality of life in patients with pulmonary arterial hypertension. Chest. 2004;126:1452–1459. CrossRef
Looper KL, Pierre A, Dunkley DM, et al. Depressive symptoms in relation to physical functioning in pulmonary hypertension. J Psychosom Res. 2009;66:221–225. CrossRef
Vanhoof J, Delcroix M, Vanvelde E, et al. Emotional symptoms and quality of life in patients with pulmonary arterial hypertension. J Heart Lung Transplant. 2014;33:800–808. CrossRef
McCollister D, Beutz M, McLaughlin V, et al. Depressive symptoms in pulmonary hypertension: prevalence and association with functional status. Psychosomatics. 2010;51(339-339):e8.
Terwee CB, Bot SDM, Boer M de, et al. Quality criteria were proposed for measurement properties of health status questionnaires. J Clin Epidemiol. 2007;60:34–42. CrossRef
Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol. 2002;40:780–788. CrossRef
McLaughlin VV, Shillington A, Rich S, et al. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation. 2002;106:1477–1482. CrossRef
Barst RJ, Galie N, Naeije R, et al. Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous trepostenil. Eur Respir J. 2006;28:1195–1203. CrossRef
Blok IM, Riel ACMJ van, Schuuring MJ, et al. Decrease in quality of life predicts mortality in adult patients with pulmonary arterial hypertension due to congenital heart disease. Neth Heart J. 2015;23:278–284. CrossRef
McKenna SP, Doughty N, Meads DM, et al. The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR). A measure of health related quality of life and quality of life for patients with pulmonary hypertension. Qual Life Res. 2006;15:103–115. CrossRef
Chen H, Rosenzweig E, Gotzkowsky SK, et al. Treatment satisfaction is associated with improved quality of life in patients treated with inhaled trepostenil for pulmonary arterial hypertension. Health Qual Life Outcomes. 2013;11:31. CrossRef
Chan L, Chin L, Kennedy M, et al. Benefits of intensive treadmill exercise training on cardiorespiratory function and quality of life in patients with pulmonary hypertension. Chest. 2013;143:333–343. CrossRef
McCabe C, Bennet M, Doughty N, et al. Patient-reported outcomes assessed by CAMPHOR questionnaire predict clinical deterioration in idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Chest. 2013;144:522–530. CrossRef
Coffin D, Duval K, Martel S, et al. Adaptation of the Cambridge Pulmonary Hypertension Outcome Review into French-Canadian and English-Canadian. Can Respir J. 2008;15:77–83. CrossRef
Coffin D, Duval K, Martel S, et al. United States Validation of the Cambridge Pulmonary Hypertension Outcome Review (CAPMHOR. J Heart Lung Transplant. 2008;27:124–130. CrossRef
Ganderton L, Jenkins S, McKenna S, et al. Validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for the Australian and New Zealand population. Respirology. 2011;16:1235–1240. CrossRef
Cima K, Twiss J, Speich R, et al. The German adaptation of the Cambridge pulmonary hypertension outcome review (CAMPHOR. Health Qual Life Outcomes. 2012;10:110–118. CrossRef
Selmovic N, Rundqvist B, Kjork E, et al. Adaptation and validation of the Cambridge pulmonary hypertension review for Sweden. Scand J Public Health. 2012;40:777–83. CrossRef
Hunt SM, McKenna SP, McEwen J, et al. The Nottingham Health Profile: Subjective Health Status and Medical Consultations. Soc Sci Med A;15A;221–9. CrossRef
Erdman RAM, Passchier J, Kooijman M, et al. The Dutch version of the Nottingham Health Profile: investigations of psychometric aspects. Psychol Rep. 1993;72:1027–1035. CrossRef
Portney L, Watkins M. Correlation. In: Cohen M, editor. Foundations of Clinical Research: Applications to Practise, 3rd edn. New Jersey: Pearson Education; 2009. pp. 523–538.
- Adaptation and validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for the Netherlands
L. van den Toorn
A. van den Bosch
K. A. Boomars
- Bohn Stafleu van Loghum
Neu im Fachgebiet Kardiologie
Mail Icon II